Invivyd, Inc. (IVVD)
D
Pipeline Grade
Financial Position (from SEC Filings)
$184.2M
Cash & Equivalents
$41.7M
Quarterly Burn Rate
13 mo
Est. Cash Runway
$231M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase3 Readout | — |
| 2026-08-01 | Phase3 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07298434 | Study of VYD2311 for the Prevention of COVID-19 | PHASE3 | Active Not Recruiting | 1,770 |
| NCT07655180 | Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a... | PHASE3 | Recruiting | 210 |
| NCT06523153 | A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants | PHASE1 | Active Not Recruiting | 40 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-07-06 | 8-K | Invivyd, Inc. (IVVD) (CIK 0001832038) - EX-99.1 | EDGAR |